eTable. Study characteristics.
| Study | Country | Recruitment period | Populationhealth status | Maximal follow-up | Comparison | Dose schedule |
|---|---|---|---|---|---|---|
| Black (2000) |
USA | Oct 1995 – Aug 1998 | 0 to 2-year-olds Immunocompetent |
Until April 1999 | PCV7 vs meningococcus type C conjugate vaccine | At 2, 4, 6 and 12–15 months of age |
| CAPITA (2014) |
Netherlands | Sep 2008 – Jan 2010 | Over 60-year-olds Immunocompetent |
3.97 years | PCV13 vs placebo | 1 dose |
| Cutts (2005) |
Gambia | Aug 2000 – Feb 2003 | 0 to 2-year-olds Immunocompetent |
Until 2.5 years of age | PCV9 vs placebo | At 11, 17 and 24 weeks of age |
| Dransfield (2012) |
USA | Apr 2007 – May 2009 | Over 60-year-olds COPD, chronically ill Immune status unclear |
2 years | PCV7 vs PPV23 | 1 dose |
| Eskola (2001)*1 |
Finland | Dec 1995 – Apr 1997 | 0 to 2-year-olds Immune status unclear |
Until 2 years of age | PCV7 vs Hepatitis B vaccine | At 2, 4, 6, and 12 months of age |
| French (2010) | Malawi | Feb 2003 – May 2007 | 16 to 59-year-olds with previous IPD Immunodeficient (88.5% HIV positive) |
4.7 years | PCV7 vs placebo | 2 doses (4-week interval) |
| Gisselsson- Solen (2011) |
Sweden | Mar 2003 – Jun 2007 | 0 to 2-year-olds with previous AOM Immunocompetent |
Until 2 years of age | PCV7 vs no vaccine | 2+1 (if age ≥6 months); 3+1 (if age <6 months) doses |
| Hammit (2014) |
Kenya | Jan 2010 – Sep 2010 | 1 to 5-year-olds Immunocompetent |
0.6 years | PCV10 vs Hepatitis A | 2 doses + standard vaccine |
| Ho (2013) |
Brazil | Oct 2005 – May 2009 | 16 to 59-year-olds Immunodeficient (HIV positive) |
0.5 years | PCV7 +PPV23 vs Placebo + PPV23 | 1 dose |
| Jackson (2013a) |
USA | Not reported | Over 60-year-olds Immunocompetent |
1 year | PCV13 vs PPV23 | 1 dose |
| Jackson (2013b) |
USA | Not reported | Over 60-year-olds Immunocompetent |
1 year | PCV13 vs PPV23 | 1 dose |
| Klugman (2003) |
South Africa | Mar 1998 – Oct 2000 | 0 to 2-year-olds Immunocompetent (6.5% HIV positive) |
3.7 years | PCV9 vs placebo | 6, 10 and 14 weeks of age |
| Lucero (2009) |
Philippines | Jul 2000 – Dec 2003 | 0–2-year-olds Immunocompetent |
Until 2 years of age | PCV11 vs placebo | 6, 10 and 14 weeks of age |
| Macintyre (2014) |
Australia | May 2005 – Dec 2007 | Over 60-year-olds, hospitalized Immune status unclear |
1 years | PCV7 + PPV23 vs PPV23 | 1 dose |
| Nachman (2003) |
USA | Jan 1996 – Jan 1998 *2 | 0 to 2-year-olds Immunodeficient (HIV positive) |
Until 2 years of age | PCV7 vs placebo | 0, 8 , and 16 weeks after enrollment, and at 15 months of age |
| O’Brien (2003)*3 |
USA | Apr 1997 – Dec 1999 | Native American 0 to 2-year-olds Immune status unclear |
Until May 2000 | PCV7 vs Neisseria meningitidis group C protein conjugate vaccine | At 2, 4, 6 and 12–15 months of age |
| Palmu (2013) |
Finland | Feb 2009 – Oct 2010 | 0 to 2-year-olds Immune status unclear |
2.9 years | PCV10 vs Hepatitis A or B vaccine | 3+1 or 2+1 doses (if age <7 months), 2+1 doses (if age 7–11 months), 2 doses (if age 12–18 months) |
| Pomat (2013) |
Papua New Guinea | May 2005 – Sep 2007 | 0 to 2-year-olds Immunocompetent |
1.5 years | PCV7+PPV23 vs no PCV7+PPV23 |
At birth, 1 and 2 months of age (neonatal group) or at ages 1, 2 and 3 months (infant group); PPV23 at 9 months for all |
| Prymula (2006) | Czech Republic, Slovakia | Oct 2000 – Sep 2002 | 0 to 2-year-olds, no acute illness Immune status unclear |
Until 2.3 years of age | PCV11 vs Hepatitis A vaccine | At 3, 4, 5 and 12–15 months of age |
| Tregnaghi (2014) | Argentina, Colombia, Panama | Jun 2007 – Dec 2008 | 0 to 2-year-olds Immunocompetent |
2.75 years | PCV10 vs Hepatitis B vaccine with Hepatitis A vaccine as booster | At 2, 4, 6 and 15–18 months of age |
| Veenhoven (2003) |
Netherlands | Apr 1998 – Jan 2001 | 0 to 7 year-olds with ≥2 AOM episodes 1 year before study entry Immunocompetent |
2.6 years | PCV7 + PPV23 vs Hepatitis A or B vaccine |
1 dose (if age 25–84 months); 2 doses (if age 12–24 months); followed by PPV23-booster |
*1Originally 3 study groups: PCV7 with nontoxic diphtheria-toxin analogue CRM197 carrier vs PCV7 meningococcal outer membrane protein complex conjugate vaccine carrier vs Hepatitis B vaccine; only PCV7 CRM197 vs Hepatitis B were analyzed
*2Randomization period
*3Only the results from one of three age groups (primary efficacy group, age 6 weeks to 7 months) Full references for these studies can be found in eSupplement 2